BOGUSLAWA KOCZON-JAREMKO, MD

** ***** ****

Avon, CT 06001

860-***-**** (cell)

ac1pam@r.postjobfree.com

CITIZENSHIP United States

EDUCATION

****-**** ********** ******* *******

Szczecin, Poland

DEGREES

1997 Doctor of Medicine

POSTGRADUATE MEDICAL TRAINING

1998-2003 Resident in Obstetrics-Gynecology

Special Independent Public Health Care Facility for Children and Young People, Szczecin, Poland

1997-1998 Rotating Internship: Special Independent Public Health Care Facility for Children and Young People

Szczecin, Poland

ACADEMIC POSITIONS

Adjunct Faculty- Instructor

Department of Community Medicine and Health Care, University of Connecticut School of Medicine

HOSPITAL APPOINTMENTS

2013 Director of Neuromuscular Research and Clinical Trials

CONTINUING EDUCATION

2015 Certificate in Public Health, University of Connecticut Health Center, School of Medicine

RESEARCH AND PROFESSIONAL EXPERIENCE

2014- Institutional Review Board Member, University of Connecticut Health Center, Farmington, CT

2013- Director of Neuromuscular Research and Clinical Trials

Neuromuscular Center, Hospital for Special Care, New Britain, CT

2011-2013 Clinical Research Coordinator Neuromuscular Center, Hospital for Special Care, New Britain, CT

2008-2011 Director of Clinical Research Fox Valley Surgical Associates, Appleton, WI

2007-2008 Clinical Research Coordinator Department of Reconstructive Sciences, University of Connecticut Health Center, Farmington, CT

2006-2007 Post-Doctoral Fellow

Center for Molecular Medicine, University of Connecticut Health Center, Farmington, CT

2005-2008 Clinical Research Coordinator and GCRC Data Analyst,

University of Connecticut Health Center Farmington, CT

2004-2006 Post-Doctoral Fellow Endocrinology/Medicine Department

University of Connecticut Health Center, Farmington, CT

2003-2004 Research Assistant

Bone Histology and Histomorphometry Center, University of Connecticut Health Center,

Farmington, CT

RESEARCH/ GRANT SUPPORT

2017-present Site Co-Principal Investigator- A Randomized, Double-Blind, Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of FLX-787-ODT for Treatment of Muscle Cramps in Adult Subjects with Motor Neuron Disease.

(Sponsor: Flex-Pharma)

2017-present Site Co-Principal Investigator- A Phase III, Open-Label Extension Study of Tirasemtiv for Patients with Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY4031)

(Sponsor: Cytokinetics)

2017-present Site Co-Principal Investigator- A 15-Week, Phase 2, Double Blind, Randomized, Placebo-Controlled, Dose Ranging Study To Investigate The Efficacy, Safety And Tolerability Of PF-06649751 In Subjects With Motor Fluctuations Due To Parkinson’s Disease

(Sponsor: Pfizer)

2016-present Site Co- Principal Investigator – A Randomized, Double-Blind, Placebo-Control Safety and Efficacy Trial of Trehalose for the Treatment of Oculopharyngeal Muscular Dystrophy (OPMD) (Sponsor: BioBlast)

2016-present Site Co-Principal Investigator- Evaluation of Microglial Activation Using PET imaging Ligand [18F]PBR-06 in Patients with Amyotrophic Lateral Sclerosis Compared to Health Volunteers

(Sponsor: Denali Therapeutics)

2016-present Site Co-Principal Investigator – A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Multiple Dose Study of CK-2127107 in Two Ascending Dose Cohorts of Patients with Spinal Muscular Atrophy (SMA) (Sponsor: Cytokinetics)

2016-present Site Co-Principal Investigator- International, multicenter, randomized, double-blind, placebo-controlled Phase III study assessing in parallel groups the Efficacy and Safety of 2 doses of PXT3003 in Patients with Charcot-Marie-Tooth Disease type 1A treated 15 months.

(Sponsor: Pharnext Pharmaceuticals)

2016-present Site Co-Principal Investigator- Investigating Microbiome Alterations in Individuals with Parkinson's Disease,

(Sponsor: Hospital for Special Care)

2016-present Principal Investigator- Cross-Section ALS Biofluid Biomarker (CABB) Study

(Sponsor: NEALS, NIH)

2015-present Site Co-Principal Investigator- A Phase III, Multi-National, Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of CK-2017357 in Patients with Amyotrophic Lateral Sclerosis

(Sponsor: Cytokinetics)

2015-present Site Co-Principal Investigator – An Open-Label, Expanded Access Protocol for Amifampyridine Phosphate (3,4-Diaminopyridine Phosphate) Treatment in Patients with Lambert-Eaton Myasthenic Syndrome (LEMS), Congenital Myasthenic Syndrome and Downbeat Nystagmus (Sponsor: Catalyst Pharmaceutical Partners)

2015-present Site Co- Principal Investigator – A Multicenter, Double Blind, Randomized, Placebo Control Study to Assess the Safety, Tolerability, and Efficacy of Intravenous Cabaletta® in Patients with Oculopharyngeal Muscular Dystrophy (OPMD) (Sponsor: Bioblast)

2015-2016 Site Co-Principal Investigator-Randomized, multicenter, double-blind, placebo-controlled, parallel-group phase III study to investigate the efficacy, safety, and tolerability of 2 different doses of IgPro20 (subcutaneous immunoglobulin) for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP)- the PATH study

(Sponsor: CSL Behring GmbH)

2014-present Principal Investigator- The ALS Patient’s Perspective on the Efficacy of the Multidisciplinary Team (Sponsor: Hospital for Special Care)

2014-2015 Site Co-Investigator-Multi-Center, Randomized Controlled Study of the NeuRx® Diaphragm Pacing System (DPS) In Participants with Amyotrophic Lateral Sclerosis (ALS)

(Sponsor: MDA, ALS, NEALS)

2014-present Site Co-Principal Investigator- MDA ALS Patient Registry, MDA

2014-present Site Co-Principal Investigator/Clinical Research Coordinator

Muscular Dystrophy Association-National Headquarters, Tucson, AZ, ALS Association- National Headquarters, Washington, D.C.

2013-2014 Site Co-Principal Investigator/Clinical Research Coordinator A Phase IIB, Multi-National, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CK-2017357 in Patients with Amyotrophic Lateral Sclerosis (ALS)

(Sponsor: Cytokinetics)

2012-2013 Site Co- Principal Investigator

An Open-Label, Multicenter, Extension study to Evaluate the Long-Term Safety and Efficacy of Dexpramipexole(BIIB050) in Subjects With Amyotrophic Lateral Sclerosis

(Sponsor: Biogen)

2011-2013 Site Co-Principal Investigator

A Randomized, Placebo-Controlled, Multi-Center Study of the Safety and Efficacy of Dexpramipexole in Subjects with ALS.

(Sponsor: Biogen)

2011-2013 Clinical Research Coordinator

Clinical Trial of Ceftriaxone in Subjects with ALS

(Sponsor: NIH, Massachusset General Hospital)

2011-2013 Clinical Research Coordinator

A Phase II, Multicenter, Double-Blind, Randomized, Placebo-Controlled Dose Titration Study to Evaluate The Safety, Tolerability, and Pharmacodynamic Effects of CK-2017357 in Patients with Amyotrophic Lateral Sclerosis (ALS)

(Sponsor: Cytokinetics)

2011-present Co-Investigator/Clinical Research Coordinator Multicenter ALS Cohort Study of Oxidative Stress And Disease Progression COSMOS study

(Sponsor: NIH,Columbia University)

2011-2012 Co-Investigator/Clinical Research Coordinator

A Phase II, Double-Blind, Randomized, Three-Way, Crossover, Placebo-Controlled, Pharmacodynamic Study of CK-2017357 in Patients with Generalized Myasthenia Gravis on Standard Therapy

(Sponsor: Cytokinetics)

2011- 2012 Co-Investigator/Clinical Research Coordinator

A Phase II, Multicenter, Double-Blind, Randomized, Placebo-Controlled Dose Titration Study to Evaluate the Safety, Tolerability, and Pharmacodynamic Effects of CK-2017357 in Patients with Amyotrophic Lateral Sclerosis (ALS)

(Sponsor: Cytokinetics)

2008-2011 Clinical Research Coordinator

Can pancreaticoduodenectomy performed at Comprehensive Community Cancer Center have comparable results as Major Tertiary Centers?

(Sponsor: Fox Valley Surgical Associates)

PROFESSIONAL AFFILIATIONS

2011-present Northeastern ALS Consortium (NEALS)

2011-present American Academy of Neurology (AAN)

OTHER LANGUAGES Polish

REFERENCES Available upon request

PUBLICATIONS

Cognitive-Behavioral Screening Reveals Prevalent Impairment in a Large Multicenter ALS Cohort (Manuscript submitted)

Mitsumoto H, Factor-Litvak P, Murphy J, Bedlack R, Katz JS et all (including Koczon-Jaremko BA)

ALS Multicenter Cohort Study of Oxidative Stress (ALS COSMOS): study methodology, recruitment, and baseline demographic and disease characteristics.

Mitsumoto H, Factor-Litvak P, Andrews H, Goetz RR, Andrews L, Rabkin JG, McElhiney M, Nieves J, Santella RM, Murphy J, Hupf J, Singleton J, Merle D, Kilty M, Heitzman D, Bedlack RS, Miller RG, Katz JS, Forshew D, Barohn RJ, Sorenson EJ, Oskarsson B, Fernandes Filho JA, Kasarskis EJ, Lomen-Hoerth C, Mozaffar T, Rollins YD, Nations SP, Swenson AJ, Shefner JM, Andrews JA, Koczon-Jaremko BA; ALS COSMOS Study Group.

Blinded evaluation of neuromuscular effects and functional improvement with Tirasemtiv in ALS (Benefit-ALS): a randomized, placebo-controlled, double-blind phase 2b trial evaluating the safety and efficacy of tirasemtiv in patients with ALS (submitted)

Shefner JM, Wolff AA, Meng L, Bian A, Lee J, Barragan D, Andrews A, and Benefit-ALS Study Group (including Koczon-Jaremko BA).

Can pancreaticoduodenectomy performed at a Comprehensive

Community Cancer Center have comparable results as Major

Tertiary Centers?

Charles Cheng, David Duppler, Boguslawa Koczon-Jaremko

Pro416Arg cherubism mutation in Sh3bp2 knock-in mice affects osteoblasts and alters bone mineral and matrix properties.

Chiachien J. Wang, I.-Ping Chen, Boguslawa Koczon-Jaremko, Adele L. Boskey, Yasuyoshi Ueki, Liisa Kuhn and Ernst J. Reichenberger

Introduction of a Phe377del Mutation in ANK Creates a Mouse Model for Craniometaphyseal Dysplasia

Chen IP, Wang CJ, Strecker S, Koczon-Jaremko B, Boskey A Reichenberger EJ.

Do cyclooxygenase-2 knockout mice have primary hyperparathyroidism?

Xu M, Choudhary S, Goltzman D, Ledgard F, Adams D,Gronowicz G, Koczon-Jaremko B., Raisz L., Pilbeam C.

Congenic Mice Provide In vivo Evidence for a Genetic Locus that Modulates Serum IGF-I and Bone Acquisition

K.M.Delahunty, K.L.Shultz, G.A.Gronowicz, B.Koczon-Jaremko, M.L. Adamo,

L.G. Horton, J. Lorenzo, L.R. Donahue, L.R. Donahue, C.

Ackert-Bicknell, B.E Kream, W.G. Beamer and C.J. Rose

T Lymphocyte Deficient Mice Lose Trabecular Bone Mass With Ovariectomy.

Lee SK, Kadono Y, Okada F, Jacquin C, Koczon-Jaremko B, Gronowicz G, Adams DJ, Aguila HL, Choi Y, Lorenzo JA

V-ATPase V(0) subunit d2-deficient mice exhibit impaired osteoclast fusion and increased bone formation

Lee SH, Rho J, Jeong D, Sul JY, Kim T, Kim N, Kang JS, Miyamoto T, Suda T, Lee SK, Pignolo RJ, Koczon-Jaremko B, Lorenzo J, Choi Y.

Macrophage migration inhibitory factor inhibits osteoclastogenesis.

Claire Jacquin, Boguslawa Koczon-Jaremko, Hector L. Aguilaa, Lin Lengc,, Richard Bucalac, George A. Kuchel, Sun-Kyeong Lee

Contact this candidate